Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

주식 순위 #2022
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
주가
$446.50
시가총액
$10.32B
변동 (1일)
-0.72%
변동 (1년)
1.73%
국가
US
거래 Madrigal Pharmaceuticals, Inc. (MDGL)

카테고리

Healthcare
Madrigal Pharmaceuticals, Inc. (MDGL)의 배당 수익률 기록
Madrigal Pharmaceuticals, Inc. (주식 심볼: MDGL)의 배당 수익률 (TTM)은 2023-12-31 기준으로 0.00%입니다.
지난 5년 평균 배당 수익률: 0.00%
Madrigal Pharmaceuticals, Inc. (MDGL)의 배당 수익률 기록: 2001 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% -100.00%
2006 0.92% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
2003 0.00% 0.00%
2002 0.00% 0.00%
2001 0.00% 0.00%
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
회사 배당 수익률 국가
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL